These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33712506)

  • 1. A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine
    Choi YH; Zhang C; Liu Z; Tu MJ; Yu AX; Yu AM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):305-315. PubMed ID: 33712506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
    Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
    Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Yang Q; Zhang S; Kang M; Dong R; Zhao J
    Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
    Li JY; Ren YP; Yuan Y; Ji SM; Zhou SP; Wang LJ; Mou ZZ; Li L; Lu W; Zhou TY
    Acta Pharmacol Sin; 2016 Jul; 37(7):930-40. PubMed ID: 27180983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia.
    Fetterly GJ; Aras U; Lal D; Murphy M; Meholick PD; Wang ES
    AAPS J; 2013 Jul; 15(3):662-73. PubMed ID: 23550025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer.
    Yuan Y; Zhou X; Ren Y; Zhou S; Wang L; Ji S; Hua M; Li L; Lu W; Zhou T
    J Pharm Sci; 2015 Dec; 104(12):4399-4408. PubMed ID: 26344053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models.
    Chen W; Chen R; Li J; Fu Y; Yang L; Su H; Yao Y; Li L; Zhou T; Lu W
    J Pharmacol Exp Ther; 2018 Jan; 364(1):13-25. PubMed ID: 29084815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft.
    Ma YH; Wang SY; Ren YP; Li J; Guo TJ; Lu W; Zhou TY
    Acta Pharmacol Sin; 2019 Feb; 40(2):243-256. PubMed ID: 29773888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Zhang H; Li Z; Wang K
    Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
    Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
    Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling of tumor growth and anticancer effects of combination therapy.
    Koch G; Walz A; Lahu G; Schropp J
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):179-97. PubMed ID: 19387803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-Pharmacodynamic Analysis of pH-Responsive Doxorubicin-Releasing Micelles with Anticancer Activity.
    Yamashita S; Imanishi A; Ueki S; Okamoto S; Kimura S; Kiriyama A
    Mol Pharm; 2024 Jul; 21(7):3173-3185. PubMed ID: 38798088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
    Ye J; Zhang R; Chai W; Du X
    Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
    Wild AT; Gandhi N; Chettiar ST; Aziz K; Gajula RP; Williams RD; Kumar R; Taparra K; Zeng J; Cades JA; Velarde E; Menon S; Geschwind JF; Cosgrove D; Pawlik TM; Maitra A; Wong J; Hales RK; Torbenson MS; Herman JM; Tran PT
    PLoS One; 2013; 8(6):e65726. PubMed ID: 23762417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
    Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.